Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Dihydrochloride in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib

conjugated bilirubin
thrombocytosis
extramedullary hematopoiesis
iron
polycythemia
  • 0 views
  • 19 Feb, 2024
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids is observed only in about 10% of patients. The most promising approaches are JAK inhibition and fecal microbiota transplantation. In this pilot study …

graft versus host disease
acute graft-versus-host disease
ruxolitinib
  • 0 views
  • 19 Feb, 2024
Low Dose Ruxolitinib in Combination With Methylprednisolone

This study is to determine the efficacy and safety of combined Low dose Ruxolitinib With Methylprednisone as Initial Therapy for the aGVHD(acute graft-versus-host disease )

methylprednisolone
regenerating islet derived protein 3
blood disorder
cancer
tumorigenicity
  • 0 views
  • 19 Feb, 2024
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

This phase II trial studies how well decitabine with ruxolitinib or fedratinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors).

myeloproliferative neoplasm
blood count
bone marrow procedure
white blood cells
hemolysis
  • 0 views
  • 19 Feb, 2024